Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology

Neurodegenerative Diseases

Volumn 15, Issue 4, 2015, Pages 243-257

  Krassnig, Stefanie ^a   Schweinzer, Cornelia ^c   Taub, Nicole ^c   Havas, Daniel ^c   Auer, Ewald ^c   Flunkert, Stefanie ^c   Schreibmayer, Wolfgang ^a   Hutter Paier, Birgit ^c   Windisch, Manfred ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b NeuroScios GmbH   (Austria)

^c QPS Austria ^*  (Austria)

Author keywords

AKT signaling; Alzheimer's disease; Amyloid precursor protein; Glycogen synthase kinase 3 beta; Protein aggregation; Transgenic mice; Synuclein

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3BETA; LENTIVIRUS VECTOR; ALPHA SYNUCLEIN; PROTEIN KINASE B;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; GENE OVEREXPRESSION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MORRIS WATER MAZE TEST; MOUSE; NERVE DEGENERATION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; STEREOTACTIC PROCEDURE; TRANSGENIC MOUSE; ANIMAL; ANXIETY; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; MEMORY; METABOLISM; PREVENTION AND CONTROL; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANXIETY; BETA-SYNUCLEIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GENETIC VECTORS; HIPPOCAMPUS; HUMANS; LENTIVIRUS; MALE; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84939562025     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000430952     Document Type: Article

References (60)

1. Crews L, Tsigelny I, Hashimoto M, Masliah E: Role of synucleins in Alzheimer's disease. Neurotox Res 2009; 16: 306-317.
2. Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, Lesne SE: Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 2012; 32: 10253-10266.
3. Ulusoy A, Di Monte D: A-synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol Neurobiol 2013; 47: 484-494.
4. George J: The synucleins. Genome Biol 2001; 3:reviews3002.3001-reviews3002.3006.
5. Oaks AW, Sidhu A: Synuclein modulation of monoamine transporters. FEBS Lett 2011; 585: 1001-1006.
6. Oaks AW, Marsh-Armstrong N, Jones JM, Credle JJ, Sidhu A: Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS One 2013; 8:e70872.
7. Chandra S, Fornai F, Kwon H-B, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC: Doubleknockout mice for α- and β-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 2004; 101: 14966-14971.
8. Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL, Chandra SS: αβγ-synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci USA 2010; 107: 19573-19578.
9. Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL: Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 2011; 31: 7264-7274.
10. Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S, Nussbaum RL, Polymeropoulos MH: Genomic organization and expression of the human β-synuclein gene (SNCB). Genomics 1998; 54: 173-175.
11. Jensen PH, Sorensen ES, Petersen TE, Gliemann J, Rasmussen LK: Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem J 1995; 310: 91-94.
12. Davidson WS, Jonas A, Clayton DF, George JM: Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998; 273: 9443-9449.
13. Eliezer D, Kutluay E, Bussell R Jr, Browne G: Conformational properties of α-synuclein in its free and lipid-associated states. J Mol Biol 2001; 307: 1061-1073.
14. Bertoncini CW, Rasia RM, Lamberto GR, Binolfi A, Zweckstetter M, Griesinger C, Fernandez CO: Structural characterization of the intrinsically unfolded protein β-synuclein, a natural negative regulator of α-synuclein aggregation. J Mol Biol 2007; 372: 708-722.
15. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
16. Uversky VN: A-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci 2008; 9: 507-540.
17. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T: Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 11282-11286.
18. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, Rohan de Silva HA, Kittel A, Saitoh T: The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14: 467-475.
19. Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, Gliemann J, Jakes R: Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J 1997; 323: 539-546.
20. Park JY, Lansbury PT Jr: β-Synuclein inhibits formation of α-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 2003; 42: 3696-3700.
21. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E: β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001; 32: 213-223.
22. Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev DE, Segal D, Gazit E: Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies. PLoS One 2010; 5:e13863.
23. Kessler JC, Rochet J-C, Lansbury PT: The Nterminal repeat domain of α-synuclein inhibits β-sheet and amyloid fibril formation. Biochemistry 2002; 42: 672-678.
24. Lee D, Paik SR, Choi KY: Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein. FEBS Lett 2004; 576: 256-260.
25. 42on the processing of AβPP. Exp Neurol 2010; 221: 18-25.
26. Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu G-M, Louis J-C, Martin F, Narhi LO, Citron M: Parkinson's disease-associated α-synuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs. J Biol Chem 2000; 275: 34574-34579.
27. Jakes R, Spillantini MG, Goedert M: Identification of two distinct synucleins from human brain. FEBS Lett 1994; 345: 27-32.
28. Seo J-H, Rah J-C, Choi SH, Shin JK, Min K, Kim H-S, Park CH, Kim S, Kim E-M, Lee S-H, Lee S, Suh SW, Suh Y-H: α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 2002; 16: 1826-1828.
29. Thomas B, Mandir AS, West N, Liu Y, Andrabi SA, Stirling W, Dawson VL, Dawson TM, Lee MK: Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation. PLoS One 2011; 6:e16706.
30. Hashimoto M, Bar-on P, Ho G, Takenouchi T, Rockenstein E, Crews L, Masliah E: Betasynuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J Biol Chem 2004; 279: 23622-23629.
31. da Costa CA, Masliah E, Checler F: Betasynuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with α-synuclein and implication for Parkinson's disease. J Biol Chem 2003; 278: 37330-37335.
32. Windisch M, Hutter-Paier B, Schreiner E: Current drugs and future hopes in the treatment of Alzheimer's disease; in Jellinger K, Schmidt R, Windisch M (eds): Ageing and Dementia: Current and Future Concepts. Vienna, Springer, 2002, vol 62, pp 149-164.
33. Masliah E, Hansen LA, Rockenstein E, Hashimoto M: Progress in the development of new treatments for combined Alzheimer's and Parkinson's diseases. Drug Dev Res 2002; 56: 282-292.
34. Fan Y, Limprasert P, Murray IVJ, Smith AC, Lee VM-Y, Trojanowski JQ, Sopher BL, La Spada AR: Beta-synuclein modulates α-synuclein neurotoxicity by reducing α-synuclein protein expression. Hum Mol Genet 2006; 15: 3002-3011.
35. Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, Gage FH, Marr R, Masliah E: An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 2004; 11: 1713-1723.
36. Windisch M, Hutter-Paier B, Schreiner E, Wronski R: Beta-synuclein-derived peptides with neuroprotective activity. J Mol Neurosci 2004; 24: 155-165.
37. Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R: Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? Curr Alzheimer Res 2007; 4: 446-457.
38. 1-42. J Neurosci Res 2001; 66: 573-582.
39. Havas D, Hutter-Paier B, Ubhi K, Rockenstein E, Crailsheim K, Masliah E, Windisch M: A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2011; 25: 231-243.
40. Mu Y, Gage FH: Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener 2011; 6: 85.
41. Kutner RH, Zhang X-Y, Reiser J: Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009; 4: 495-505.
42. Athos J, Storm DR: High precision stereotaxic surgery in mice. Curr Protoc Neurosci 2001; Appendix 4: Appendix 4A.
43. Walf AA, Frye CA: The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007; 2: 322-328.
44. Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
45. Loffler T, Flunkert S, Havas D, Santha M, Hutter-Paier B, Steyrer E, Windisch M: Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiol Aging 2013; 34: 2379-2388.
46. SLmice: further value of this in vivo model of Alzheimer's disease. J Neuroinflamm 2014; 11: 84.
47. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden T: Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012; 13: 134.
48. Haugabook SJ, Yager DM, Eckman EA, Golde TE, Younkin SG, Eckman CB: High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid β peptide (Aβ). J Neurosci Methods 2001; 108: 171-179.
49. Czvitkovich S, Duller S, Mathiesen E, Lorenzoni K, Imbimbo B, Hutter-Paier B, Windisch M, Wronski R: Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line. J Mol Neurosci 2011; 43: 257-267.
50. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E: Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001; 914: 48-56.
51. Beyer K, Domingo-Sabat M, Santos C, Tolosa E, Ferrer I, Ariza A: The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain 2010; 133: 3724-3733.
52. Zhang L, Yu S, Zhang R, Xing Y, Li Y, Li L: Tetrahydroxystilbene glucoside antagonizes age-related α-synuclein overexpression in the hippocampus of APP transgenic mouse model of Alzheimer's disease. Restor Neurol Neurosci 2013; 31: 41-52.
53. Taschenberger G, Toloe J, Tereshchenko J, Akerboom J, Wales P, Benz R, Becker S, Outeiro TF, Looger LL, Bahr M, Zweckstetter M, Kugler S: β-Synuclein aggregates and induces neurodegeneration in dopaminergic neurons. Ann Neurol 2013; 74: 109-118.
54. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, Trojanowski JQ, Ishikawa A, Idezuka J, Murata M, Toda T, Bird TD, Leverenz JB, Tsuji S, La Spada AR: Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004; 63: 805-811.
55. Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, Nakai M, Waragai M, Takenouchi T, Takamatsu Y, Wei J, Rockenstein E, La Spada AR, Masliah E, Inoue S, Hashimoto M: A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun 2010; 1: 110.
56. Kao AW, Racine CA, Quitania LC, Kramer JH, Christine CW, Miller BL: Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord 2009; 23: 365-370.
57. Marxreiter F, Ettle B, May VEL, Esmer H, Patrick C, Kragh CL, Klucken J, Winner B, Riess O, Winkler J, Masliah E, Nuber S: Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol Dis 2013; 59: 38-51.
58. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.
59. DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P, Hashimoto T, Fan Z, Hudry E, Barroeta I, Sereno L, Rodriguez M, Sanchez MB, Hyman BT, Gomez-Isla T: Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis 2012; 45: 425-437.
60. Hurtado DE, Molina-Porcel L, Carroll JC, MacDonald C, Aboagye AK, Trojanowski JQ, Lee VM: Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 2012; 32: 7392-7402.